Most Hsp70 chaperone inhibitors exert anti-cancer effects; however, their high cytotoxicity proposed the use of peptide fragments of the chaperone as safer modulators of its activity and as complements to customary drugs. One such peptide, ICit-2, was found to inhibit substrate-binding and refolding activities of the chaperone. Using various approaches, we established that ICit-2 binds Hsp70, which may explain its inhibitory action. ICit-2 penetrates A-431 cancer cells and, in combination with doxorubicin (Dox), enhances the cytotoxicity and growth inhibitory effect of the drug. Similarly, using the B16 mouse melanoma model, we found that ICit-2 inhibits the rate of tumor growth by 48% compared to Dox alone, confirming that the peptide can be employed to sensitize resistant tumors to cytostatic medicines.
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Keywords: anti-cancer; chaperone; Hsp70; molecular docking; peptidomimetic; substrate-binding The molecular chaperone Hsp70 plays a significant role in the protection of tumor cells from a great number of anti-cancer drugs, particularly those inducing apoptosis [1] . Cancer cells typically contain an increased level of Hsp70 and so its expression or its function should be targeted to overcome chaperonebased protection. To date, only a few Hsp70 chaperone inhibitors have been tested in various cell and animal tumor models [2] .
One of the small molecule inhibitors of Hsp70, VER-155008, an adenosine derivative with a high affinity to the nucleotide-binding domain (NBD) of the protein, was found to inhibit growth and stimulate apoptosis of cells from several tumor lines [3] . Another Hsp70 inhibitor, 2-phenylethynesulfonamide (known as pifithrin-l or PES), also recognizes NBD, causing conformational alterations and the disruption of its interaction with co-chaperones [4] . Similarly, JG-98, a novel compound that dissociates the link between Hsp70 and Bag-3, suppresses pro-survival signaling and reduces the proliferation rate in a variety of cancer cells [5] . The MKT-077 molecule was also shown to bind to Hsp70 and thus inhibit the chaperone activity that leads to tumor cell senescence [6, 7] .
Most of Hsp70 inhibitors display anti-cancer activity in cellular and animal tumor models; however, their clinical application is hampered by their high cytotoxicity [8] . Searching for safer Hsp70 inhibitors, we focused on peptides and identified a study in which A17 peptide aptamer over-expressed in tumor cells inhibited Hsp70 chaperone activity and, in combination with cisplatin or etoposide, demonstrated a pronounced anti-tumor effect [9] . Moreover, the expression of A17 in combination with Hsp90
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inhibitor increased the radiosensitivity of human lung and breast cancer cells [10] . Both studies prompted a search for the peptides that are able to inhibit the Hsp70 chaperone and penetrate a living cell. Accordingly, we turned to the Hsp70 molecule because it contains several fascinating amino acid sequences that have the ability to penetrate a cell (KST peptide) [11] , as well as the capacity to induce a natural killer cell-mediated immune response [12] . Additionally, peptides from the substrate-binding domain (SBD) and linker region of Hsp70 are participants in interdomain interactions and oligomerization of the protein [13], suggesting their involvement in chaperone function [14] . We obtained the library of Hsp70 (HSPA1A) peptides and analyzed their ability to inhibit the chaperone function of the protein. One of the peptides was shown to penetrate A-431 human carcinoma cells and to enhance the anti-cancer effect of the known pharmacological compound doxorubicin (Dox).
Materials and methods

Peptides and Hsp70
The peptide library containing 91 15-mer oligopeptide parts of Hsp70 (HSPA1A, 641 amino acid sequence) was synthesized by BioSynthesis (Lewisville, TX, USA). Recombinant Hsp70 was purified from lysate of Escherichia coli transformed with pMHsp70 plasmid using two-step chromatography [15] .
Cells
A-431 human squamous carcinoma cells were obtained from the Russian Collection of Cell Cultures (Institute of Cytology, St Petersburg, Russia). Cells were cultured using Dulbecco's modified Eagle's medium medium with 10% FBS (Gibco, Gaithersburg, MD, USA).
To estimate the toxic effect of ICit-2 in combined therapy, we pre-incubated A-431 cells with ICit-2 peptide and, 2 h later, Dox was added to the culture. At certain time points, cell medium aliquots were collected and subjected to the analysis of lactate dehydrogenase (LDH) activity with aid CytoTox96Ò Reagent (Promega, Madison, WI, USA). LDH is known to be exclusively cytoplasmic enzyme and its exogenous appearance indicates the development of cell death. Measurement of cell growth dynamic was performed using an xCELLigence RTCA DP instrument (ACEA BiosciencesÒ, Inc., San Diego, CA, USA). The cell index measured by this technique is proportional to impedance, with cells attached to the surface of special bottom electrode increasing the value, whereas cell death or growth inhibition reduces impedance.
Chaperone assays
To measure the substrate-binding activity of Hsp70, we employed a method that has been described previously [16] .
For the refolding assay, firefly luciferase was denatured by incubation in 50 mM Hepes-KOH, pH 7.5, 10 mM KCl, 5 mM MgCl 2 and 8 M urea. The luciferase solution was then diluted 100-fold and mixed with an equal volume of refolding mixture containing heat-shocked A-431cell lysate (500 lgÁmL À1 in 20 mM Hepes-NaOH, pH 7.5, 100 mM NaCl, 1.5 mM MgCl 2 , 0.5 mM EDTA, 0.025% NP-40 and 0.5 mM dithiothreitol); recombinant Hsp70 (60 lg‧mL À1 )
pre-incubated with peptides to be tested, creatine phosphate (10 mM), creatine phosphokinase (16 U‧mL À1 ), ATP (2 mM) and dithiothreitol (2 mM) were added to enhance the refolding process. The mixture was incubated at 37°C and at different time points the reaction was triggered by the addition of an equal volume of Bright-GLO Luciferase Assay System Buffer (Promega); luminescence was measured with the aid of a Charity Fluorofot reader (Probanauchpribor, St Petersburg, Russia).
Analysis of ICit-2 binding to Hsp70
To explore the ability of a peptide to interact with Hsp70, we used a modified drug affinity responsive target stability assay (DARTS) [17] . Mixtures of Hsp70 and ICit-2 after incubation with trypsin-agarose (Sigma-Aldrich, St Louis, MO, USA) were analyzed by PAGE and immunoblotting using rabbit polyclonal anti-Hsp70 antibodies [18] . The binding capacity of ICit-2 to Hsp70 was measured with the aid of microscale thermophoresis (MST) [19] . Hsp70 was labeled with Alexa Fluor 488 Dye (Thermo Fisher Scientific Inc., Waltham, MA, USA). In a typical MST experiment, the concentration of Alexa Fluor 488-labeled Hsp70 was kept constant (8 lM), whereas the concentration of nonlabeled ICit-2 dissolved in 20 mM Tris HCl buffer, pH 7.5, 20 mM NaCl, 10 mM MgCl 2 , 0.5% Tween 20 and 10% glycerol varied between 1.2 nm and 40 lM. After 1 h of incubation at room temperature, samples were loaded into MST NT.115 glass capillaries and MST analysis was performed using the Monolith NT.115 (Nanotemper Technology, M€ unchen, Germany) equipped with NANOTEMPER ANALYSIS software, version 1.2.101 (Nanotemper Technology).
To investigate the binding site for ICit-2 peptide on the Hsp70 molecule, we used molecular docking. The protocols employed are described in the Supporting information.
Cell-penetrating capacity
For luminescent microscopy, A-431cells were incubated with biotinylated ICit-2 and KST (positive control) [11] peptides (10 lM) for 2 h, fixed and stained by avidin-FITC and Phalloidin-633 (Thermo Fisher Scientific Inc.). The samples were analyzed using a TCS SP5 confocal microscope (Leica Microsystems, Wetzlar, Germany). For flow cytometry studies, cells were incubated with pre-made complex of 10 lM biotinylated ICit-2 or KST with avidin-FITC (1 : 1) for 2 h and analyzed using CytoFLEX flow cytometer (Beckman Coulter, Fullerton, CA, USA) as described previously [11] .
Combined therapy in vivo
Three-month-old C57BL/6 mice were engrafted with B16 cells (0.5 9 10 6 ) and divided into five groups (n = 7 each): 
Statistical analysis
A nonparametric Mann-Whitney U-test was applied for the statistical analysis. P < 0.05 was considered statistically significant. All reported data are the average of at least three experiments.
Results
Chaperone assays reveal peptides with Hsp70-modulating activity
The analysis of Hsp70 peptide activity was carried out first with the aid of a substrate-binding assay in which Hsp70 chaperone interacts with the irreversibly denatured lactalbumin. To validate the assay, we employed well-known Hsp70 inhibitor MKT-077 [6] and found that it reduced binding by 53% at a concentration of 2 lM (Fig. 1A) . 15-mer peptides, covering the Hsp70 amino acid sequence and at concentrations of 2 and 10 lM, were pre-incubated with pure recombinant Hsp70 before application to wells with substrate protein. We found that the peptides were able to modulate the substrate-binding activity of Hsp70 and also that five of them (peptides 6, 7, 50, 56 and 62) inhibited Hsp70 binding by 25-65% at a concentration of 2 lM (Fig. 1A) . The refolding assay was employed to test the ability of the peptides to inhibit the refolding function of Hsp70. The validity of the refolding assay was also established in experiments with MKT-077, which reduced the rate of luciferase activity recovery by 80% at a concentration of 2 lM (Fig. 1B) . Four of 91 tested peptides (6, 7, 10 and 11) could inhibit the refolding activity of Hsp70 by 10-20% at a concentration of 2 lM and by 30-70% at a concentration of 10 lM (Fig. 1B) .
Peptides 6 (RTTPSYVAFTDTERL, residues 36-50) and 7 (AFTDTERLIGDAAKN, residues 43-57) demonstrated an inhibitory effect on both substratebinding and refolding Hsp70 activities and therefore were chosen for further analysis. Based on a combined amino acid sequence of peptides 6 and 7, three-secondgeneration 11-mer peptides were synthesized: ICit-1 (GGRTTPSYVAFTD), ICit-2 (GGYVAFTDTERLI) and ICit-3 (GGDTERLIGDAAKN). The three newer, as well as two original, peptides were tested in the substrate-binding assay with pure recombinant Hsp70. The most effective peptide ICit-2 was able to reduce the substrate-binding activity of Hsp70 by 72% (Fig. 1C ) versus 60% and 57% for peptides 6 and 7, respectively (Fig. 1A) . We also investigated whether the new generation peptides could reduce the rate of luciferase recovery in the refolding assay and found that the inhibitory effect was maximal for ICit-2 and that the luciferase luminescence was reduced by 30% (2 lM of ICit-2), thus demonstrating a higher inhibitory capacity compared to the parent peptides (Fig. 1D) . The peptide ICit-2 was thus considered to be the most efficient inhibitor of Hsp70 chaperone refolding activity and was employed in further research.
Interaction of ICit-2 with Hsp70
The anti-chaperone effects of ICit-2 peptide may occur as a result of its binding to the Hsp70 molecule and the masking sites important for the substrate-binding and refolding functions of the chaperone. To investigate this proposal, we employed three different methods. First, using a DARTS assay, we found that trypsinolysis of pure Hsp70 led to the formation of smaller fragments that were recognized by rabbit polyclonal antibody on the blotting membrane. Interaction between protein and ICit-2 reduced protein availability to trypsin, and the initial band corresponding to 70 kDa was still abundant, whereas the reduction of the ICit-2 : Hsp70 ratio paralleled the original band disappearance starting at a concentration of 2 lM ICit-2 ( Fig. 2A) . To quantify the interaction between Hsp70 and ICit-2, we employed MST. Pure recombinant Hsp70 was mixed with ICit-2 at concentrations of 1.2 nM to 40 lM and a typical curve showing the dependence of normalized fluorescence (ΔF norm ) on the concentration of the ligand was obtained; the resulting value of K D was 580 AE 60 nM (Fig. 2B) .
Using a molecular dynamics simulation approach, we predicted the peptide-binding site on the Hsp70 molecule. Three probable sites are shown in Fig. 2C , D, and any of these may reflect the probable position of the binding site because the interaction parameters are relatively labile in all cases. The first site is a large region of the NBD surface around the ATP-binding site. The crucial residues in this site include Gln33, Arg269 and Ser276, which are located at the outer part of the ATP/ADP-binding pocket (Table 1) . A region around Lys348 can be considered as part of the same site. The second probable binding site is an N-end of the SBD, including the inter-domain linker, which is important for the opening/closing cycle of the Hsp70 molecule. Finally, a less probable binding site with a relatively big binding energy but low occupancy was observed in NBD on the site opposite to the ATP/ ADP-binding pocket. However, deep penetration of the peptide into the Hsp70 molecule could affect the ATP/ADP binding site.
ICit-2 peptide penetrates a living cell
A factor with the ability to inhibit the activity of intracellular Hsp70 must cross the plasma membrane. To detect the biotinylated ICit-2 peptide inside a cell, we employed an immunocytochemical method with avidin-FITC as the strain. As a positive control, we used KST peptide, which had been shown previously to penetrate cells of various origins [11] . A-431 cells were incubated with ICit-2 or KST peptides (10 lM) and stained with avidin-FITC (green) or Phalloidin-633 (red) to obtain a pattern of actin distribution throughout the cytoplasm. Both peptides penetrated cells and were visible as diffuse inclusions inside the tangle of actin filaments (Fig. 3A) .
To estimate the number of cells able to incorporate ICit-2, we formed an equimolar complex of the peptide (or KST) with avidin-FITC and incubated A-431 cells with the construct. According to the data obtained from the flow cytometry studies, 36.2% of cells were capable to accept ICit-2 carrying avidin-FITC after 1 h of incubation, whereas the KST-avidin-FITC complex was found to penetrate 82.1% of cells (Fig. 3B ).
ICit-2 enhances the anticancer effect of Dox both in vitro and in vivo
ICit-2 oligopeptide was confirmed to inhibit Hsp70 chaperone activity and to penetrate the living cell. Next, we checked the toxicity of the peptide and its ability to enhance the cytotoxic effect of Dox both in vitro and in vivo.
ICit-2 at any of the concentrations tested had no effect on cell growth (Fig. S1 ). The addition of 10 and 20 lM ICit-2 showed an enhancement of the Dox cytotoxic effect by 35% and 37%, respectively, as demonstrated with the aid of xCELLigence technology (Fig. 4A) . Comparable results were obtained in studies with respect to measurements of the activity of LDH in conditioned medium from A-431 cells treated with ICit-2, or with Dox using the CytoTox96Ò assay (Promega). After 36 h of incubation, Dox alone at a concentration of 5 lM resulted in 40% cell mortality, whereas the mortality index was increased to 60% and 75%, respectively, when ICit-2 was added at concentrations of 10 and 20 lM (Fig. 4B) . Importantly, the peptide itself at the selected concentrations has no noticeable toxicity (Fig. S2) .
To investigate the combinational anti-cancer effect of ICit-2 with Dox in vivo, we used a B16 mouse melanoma model. Tumor size was measured on day 20 after inoculation of B16 melanoma cells and on day 10 after beginning the treatment with Dox, alone or in combination with ICit-2. Dox treatment lead to a 45% reduction in tumor growth, whereas, when it was combined with ICit-2, there was an even higher growth reduction of 70% (Fig. 4C) . In addition, we evaluated the lifespan of tumor-bearing mice in different treatment groups. Depicting the data in Kaplan-Meier form showed that the average life expectancy in the group with combined treatment was 41 days, whereas Dox-treated animals had an average lifespan of 37 days (Fig. 4D) .
Discussion
Data obtained in past two decades show that inhibition of Hsp70 activity with drugs such as MKT-077 or PES may induce cell death in the manner of known anti-cancer drugs [20] . However, the elevated toxicity of these substances limits their clinical application and therefore we focused our search on a nontoxic inhibitor of Hsp70 activity. Previously, it was shown that oligopetides with 10-20 amino acid residues, such as drosocin and apidaecin, can interact with the SBD of prokaryotic Hsp70 analogue, DnaK, and inhibit the substrate-binding function of this chaperone [21] . We suggested that the parts of Hsp70 itself may influence its activity by binding to certain sites of the chaperone and masking them. Using two novel assays for Hsp70 activity modulators [22] , we found four peptides that had the potency to inhibit the substrate-binding and refolding activity of Hsp70. With this indicating that maximal inhibitory activity matches the overlapping region of peptides 6 and 7, we generated a new panel of the peptides and, after the new round of screening, peptide ICit-2 was chosen for further studies.
Most of the Hsp70 inhibitors affect chaperone activity by binding to its molecule; this was established for PES and VER-155008 [23] . Using MST, we showed that interaction between Hsp70 and ICit-2 is characterized by a value of K D of 0.58 lM, which is close to the K D in the micromolar range for MKT-077, 2,5 0 - Crucial for the binding residues are shown in bold. thiodipyrimidine derivatives and other Hsp70 binders [24, 25] . Using molecular docking, we revealed possible sites targeted by the ICit-2, giving rise to two hypotheses of how binding affects Hsp70 functioning (Fig. 2C,  D) . First, ICit-2 interacts with the NBD-SBD linker, which is critical for the opening/closing cycle of chaperone molecule [26, 27] . Hydrophobic leucines 392-394 belonging to the linker part are involved in the interaction with the peptide (Table 1) and can also affect the Asp390 that is important for the conformational changes occurring during the chaperone functional cycle [27] . Moreover, leucines 392-394 are implicated in the process of Hsp70 oligomerization, which again influences chaperone function [13, 14] . The second binding site is located near the ATP binding site [28] and ICit-2 can block the site and suppress its interaction with ATP. This effect is quite similar to that of VER-155008, which interacts with Asp23, Lys271, Arg272 and Ser275, closing the ATP-binding pocket, preventing ATP binding and causing defects in Hsp70 interactions with co-chaperones [23, 29] . Finally, a less probable binding site with a relatively big binding energy but low occupancy was observed in NBD on the site opposite to the ATP/ADP-binding pocket. However, deep penetration of the peptide into the Hsp70 molecule could affect the ATP/ADP binding site. An important property of any anti-cancer drug is its ability to penetrate a cell and thus this was investigated using biotinylated ICit-2 and avidin-FITC as a label. Data from microscopy and flow cytometry studies revealed that ICit-2 is able to penetrate the cell even in complex with avidin, a molecule with a molecular mass > 200 kDa (Fig. 3B) . Previously, two other Hsp70 peptide fragments, KST and TKD, were found to cross the plasma membrane and it can be speculated that the multiple effects of the so-called exogenous Hsp70 might be a result of translocations inside and outside a living cell [11, 12] .
Most of the Hsp70-targeting substances are considerably toxic. For example, treatment with 10 lM MKT-077 results in the death of 60% of the A375 cell population [30] and causes miscellaneous toxicity in clinical trials [31] . A similar value of EC 50 (10-30 lM) was found for PES [32] . ICit-2 showed no statistically significant toxic effect even when applied at 20 lM to A-431 cells or 2 mg‧kg À1 to animals ( Figs 4D and S2 ).
The present study aimed to demonstrate the effect of tumor sensitization to anticancer medicine. We observed that ICit-2 elevated the toxicity of Dox by 50% in an A-431 cell model and reduced the rate of tumor growth in a mouse melanoma model by 56% (Fig. 4C) , confirming its clinical promise. This successful example of combinational therapy based on a chaperone inhibitor and a clinically approved drug may be complemented by data reported by McKeon et al. [33] from a study employing PES and cisplatin.
In conclusion, a peptide fragment of Hsp70 was found with the ability to inhibit both substrate-binding and refolding activities; this novel, nontoxic Hsp70 inhibitor enhances the activity of the classic anticancer drug Dox and can be employed in the combinational therapy of tumors resistant to cytostatic drugs. 
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